Published Clinical research


Ayahuasca is a sacred plant teacher from the Amazon with benefits for PTSD, anxiety, depression, addiction, and spiritual growth.

July 16, 2021

Frontiers in Psychiatry

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study

July 13, 2021

Scientific Reports

Associations between lifetime classic psychedelic use and cardiometabolic diseases

June 9, 2021

Frontiers in Psychiatry

Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

May 19, 2021

Frontiers in Pharmacology

Relational Processes in Ayahuasca Groups of Palestinians and Israelis

May 19, 2021

Frontiers in Pharmacology

Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center

May 5, 2021

Frontiers in Pharmacology

The Shipibo Ceremonial Use of Ayahuasca to Promote Well-Being: An Observational Study

April 12, 2021

Frontiers in Pharmacology

Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey

March 25, 2021

Frontiers in Pharmacology

Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness

April 23, 2019

PLoS One

Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT

June 15, 2018

Psychological Medicine

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

May 8, 2018

Frontiers in Psychiatry

Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls

April 24, 2018

Frontiers in Psychiatry

Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca

March 20, 2018

Frontiers in Pharmacology

Four Weekly Ayahuasca Sessions Lead to Increases in “Acceptance” Capacities: A Comparison Study With a Standard 8-Week Mindfulness Training Program

July 15, 2017

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

ALSUntangled 40: Ayahuasca

July 13, 2017

Scientific Reports

The alkaloids of Banisteriopsis caapi, the plant source of the Amazonian hallucinogen Ayahuasca, stimulate adult neurogenesis in vitro

March 2, 2016

Frontiers in Pharmacology

The Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization

May 31, 2010

Drug Alcohol Dependence

Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users

February 10, 2010

Journal of Ethnopharmacology

Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease

January, 2007


Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids


Help us raise money for our education & advocacy causes